Patient characteristics (N = 211)
| Variable . | Tac/Sir . | Tac/Mtx . | P value . |
|---|---|---|---|
| Number of patients | 104 | 107 | |
| Underwent transplantation | 104 (100) | 107 (100) | |
| Age, median, y (range) | 45 (19-59) | 41 (13-58) | .079 |
| Male sex | 53 (51) | 48 (45) | .41 |
| Primary malignancy | .19 | ||
| Acute myelogenous leukemia | 46 (44) | 40 (37) | |
| Acute lymphoblastic leukemia | 38 (37) | 53 (50) | |
| Chronic myelogenous leukemia | 8 (8) | 9 (8) | |
| Myelodysplastic syndrome | 11 (11) | 5 (5) | |
| Acute biphenotypic leukemia | 1 (1) | 0 (0) | |
| Disease status at transplantation | |||
| Acute myelogenous leukemia | .58 | ||
| 1st complete remission | 37 (80) | 34 (85) | |
| 2nd complete remission | 9 (20) | 6 (15) | |
| Acute lymphoblastic leukemia | .86 | ||
| 1st complete remission | 31 (82) | 44 (83) | |
| 2nd complete remission | 7 (18) | 9 (17) | |
| Chronic myelogenous leukemia | .60 | ||
| Chronic phase | 7 (88) | 7 (78) | |
| Accelerated phase | 1 (13) | 2 (22) | |
| Acute biphenotypic leukemia | |||
| 1st complete remission | 1 | ||
| Karnofsky score | .97 | ||
| 90-100% | 72 (69) | 77 (72) | |
| <90% | 32 (31) | 30 (28) | |
| Recipient-donor CMV status | .028 | ||
| +/+ | 41 (39) | 33 (31) | |
| +/− | 21 (20) | 34 (32) | |
| −/+ | 9 (9) | 18 (17) | |
| −/− | 27 (26) | 17 (16) | |
| Missing | 6 (6) | 5 (5) | |
| Recipient CMV status | .66 | ||
| + | 66 (63) | 71 (66) | |
| − | 38 (37) | 36 (34) | |
| Donor-recipient sex match | .77 | ||
| Female-male | 29 (28) | 30 (28) | |
| Conditioning regimen | |||
| Cyclophosphamide/total body irradiation | 85 (82) | 84 (79) | .56 |
| Etoposide/total body irradiation | 19 (18) | 23 (22) |
| Variable . | Tac/Sir . | Tac/Mtx . | P value . |
|---|---|---|---|
| Number of patients | 104 | 107 | |
| Underwent transplantation | 104 (100) | 107 (100) | |
| Age, median, y (range) | 45 (19-59) | 41 (13-58) | .079 |
| Male sex | 53 (51) | 48 (45) | .41 |
| Primary malignancy | .19 | ||
| Acute myelogenous leukemia | 46 (44) | 40 (37) | |
| Acute lymphoblastic leukemia | 38 (37) | 53 (50) | |
| Chronic myelogenous leukemia | 8 (8) | 9 (8) | |
| Myelodysplastic syndrome | 11 (11) | 5 (5) | |
| Acute biphenotypic leukemia | 1 (1) | 0 (0) | |
| Disease status at transplantation | |||
| Acute myelogenous leukemia | .58 | ||
| 1st complete remission | 37 (80) | 34 (85) | |
| 2nd complete remission | 9 (20) | 6 (15) | |
| Acute lymphoblastic leukemia | .86 | ||
| 1st complete remission | 31 (82) | 44 (83) | |
| 2nd complete remission | 7 (18) | 9 (17) | |
| Chronic myelogenous leukemia | .60 | ||
| Chronic phase | 7 (88) | 7 (78) | |
| Accelerated phase | 1 (13) | 2 (22) | |
| Acute biphenotypic leukemia | |||
| 1st complete remission | 1 | ||
| Karnofsky score | .97 | ||
| 90-100% | 72 (69) | 77 (72) | |
| <90% | 32 (31) | 30 (28) | |
| Recipient-donor CMV status | .028 | ||
| +/+ | 41 (39) | 33 (31) | |
| +/− | 21 (20) | 34 (32) | |
| −/+ | 9 (9) | 18 (17) | |
| −/− | 27 (26) | 17 (16) | |
| Missing | 6 (6) | 5 (5) | |
| Recipient CMV status | .66 | ||
| + | 66 (63) | 71 (66) | |
| − | 38 (37) | 36 (34) | |
| Donor-recipient sex match | .77 | ||
| Female-male | 29 (28) | 30 (28) | |
| Conditioning regimen | |||
| Cyclophosphamide/total body irradiation | 85 (82) | 84 (79) | .56 |
| Etoposide/total body irradiation | 19 (18) | 23 (22) |